TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03384186
Drug: Danicopan Modified Release Prototype 1
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicopan (400 milligrams \[mg\]) oral tablet.
Study: NCT03384186
Drug: Danicopan Modified Release Prototype 2
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicopan (400 mg) oral tablet.
Study: NCT03384186
Drug: Danicopan Modified Release Prototype 3
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicopan (800 mg) oral tablet.
Study: NCT03326063
Drug: Ifetroban
Normalized name: Ifetroban
DrugBank: Ifetroban (DB12321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
Study: NCT03573245
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid effect on perioperative bleeding in orthopedic surgery
Study: NCT02622477
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
Study: NCT00060671
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00060671
Drug: Pixantrone (BBR 2778)
DrugBank: Pixantrone (DB06193)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01404650
Drug: AUY922
Normalized name: AUY922
DrugBank: AUY922 (DB11881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
Study: NCT02271893
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
Study: NCT00989508
Drug: Perhexiline
Normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
Study: NCT02524561
Drug: Active Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Study: NCT01107067
Drug: Sustanon
Normalized name: SUSTAGEN PWDR CHOCOLATE
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg/21 days
Study: NCT00283543
Drug: Gliadel Wafer
Normalized name: GLIADEL Wafer 7.7 MG Intracavitary Drug Implant
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00283543
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03465722
Drug: avapritinib
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
Study: NCT03465722
Drug: regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
Study: NCT01242566
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally 150-200 mg/m2/day for 5 consecutive days every 4 week
Study: NCT02099084
Drug: Teduglutide
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
Study: NCT00737932
Drug: Laquinimod
Normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
Study: NCT01545765
Drug: Lidocaine 7% + Tetracaine 7% cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
Study: NCT02379195
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
Study: NCT02379195
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
Study: NCT02379195
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
Study: NCT03489044
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks
Study: NCT03468777
Drug: Lumicitabine
Normalized name: Lumicitabine
DrugBank: Lumicitabine (DB14808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
Study: NCT03468777
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
Study: NCT03468777
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
Study: NCT00003631
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003631
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003631
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003631
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003631
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003631
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00996658
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin tablets once daily
Study: NCT03138785
Drug: topical voriconazole / levofloxacin systemic itraconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
Study: NCT04339413
Drug: Gantenerumab
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab was administered as SC injection Q4W.
Study: NCT00457678
Drug: Visudyne
Normalized name: Visudyne
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00457678
Drug: Lucentis
Normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00457678
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00903422
Drug: eltrombopag olamine
Normalized name: Eltrombopag Olamine
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: thrombopoietin receptor agonist
Study: NCT00075426
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01675128
Drug: ISIS 183750
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01675128
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02524145
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
Study: NCT02524145
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
Study: NCT02524145
Drug: Isoproterenol
Normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
Study: NCT00832585
Drug: Alefacept
Normalized name: Alefacept
DrugBank: Alefacept (DB00092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alefacept 15mg IM every week for 12 weeks
Study: NCT00907985
Drug: Vofopitant
Normalized name: Vofopitant
DrugBank: Vofopitant (DB12436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
Study: NCT00907985
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
Study: NCT00234039
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02393820
Drug: pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: treatment will be given until progression or unacceptable toxicity .
Study: NCT00872274
Drug: sumatriptan 100mg
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02109289
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept is a tumor necrosis factor antagonist
Study: NCT02224131
Drug: Aspirin and clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)
Study: NCT02224131
Drug: Aspirin and clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: aspirin and clopidogrel maintenance doses (according to international guidelines)
Study: NCT04224922
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04224922
Drug: Carboplatinum
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04224922
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00997984
Drug: extended-release guanfacine hydrochloride (SPD503)
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dosed in AM
Study: NCT02496455
Drug: Opioid Tramadol
Normalized name: tramadol and other non-opioid analgesics
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
Study: NCT00997984
Drug: extended-release guanfacine hydrochloride
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosed in the PM
Study: NCT00362882
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00362882
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01050751
Drug: Lersivirine
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Lersivirine 750 mg (1 x 750 mg) single dose
Study: NCT01050751
Drug: Lersivirine
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Lersivirine 750 mg (3 x 250 mg) single dose
Study: NCT00093262
Drug: clevidipine
Normalized name: Clevidipine
DrugBank: Clevidipine (DB04920)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02325024
Drug: Sativex
Normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
Study: NCT00325507
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6
Study: NCT01835119
Drug: gum
Normalized name: gum
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gum
Study: NCT04430361
Drug: Megestrol
Normalized name: Megestrol
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.
Study: NCT04430361
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
Study: NCT01715363
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01715363
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02075086
Drug: Xelox or Xeliri Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy treatment
Study: NCT00933439
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
Study: NCT02691416
Drug: propofol postconditioning
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
Study: NCT02691416
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5%-2% sevoflurane with BIS 40-60
Study: NCT06071156
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences
Study: NCT00275431
Drug: AT-101
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03884348
Drug: proton pump inhibitor, amoxicillin, metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
Study: NCT01999686
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01999686
Drug: Placebo metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
Study: NCT00768261
Drug: Memantine (Namenda®)
Normalized name: memantine Oral Tablet [Namenda]
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
Study: NCT00768261
Drug: Donepezil (Aricept®)
Normalized name: donepezil Oral Tablet [Aricept]
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
Study: NCT01111227
Drug: Propofol and isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of two anesthetic drugs
Study: NCT02593903
Drug: Septra
Normalized name: Septra
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02653339
Drug: Qufeng Shengshi Fang and Loratadine
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD
Study: NCT02653339
Drug: Loratadine
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD
Study: NCT01840488
Drug: Irosustat (BN83495)
Normalized name: Irosustat
DrugBank: Irosustat (DB02292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three parts (A, B \& C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression.
Study: NCT00373646
Drug: Thalidomide, Pharmion
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg p.o. daily
Study: NCT01021176
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
Study: NCT02522169
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year.
Study: NCT03686878
Drug: Lifitegrast
Normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifitegrast used twice a day
Study: NCT00625586
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 weekly, intravenously
Study: NCT00148031
Drug: Pegylated Interferon and Ribavirin
Normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both groups with receive the same medical intervention but offered at different locations
Study: NCT00243867
Drug: Taxoprexin
Normalized name: Talotrexin
DrugBank: Talotrexin (DB06178)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes